ResMed study offers new insights into treatment of central sleep apnoea

Medical Company Product News

ResMed has highlighted the findings of a new big data analysis that offers new insights into the best ways of treating central sleep apnoea (CSA).

The research indicated that people with treatment-emergent CSA have a significantly greater risk of terminating positive airway pressure (PAP) treatment, although a higher risk of ending therapy was observed among all CSA patients.

“ResMed has released new study data showing that patients with treatment-emergent central sleep apnoea are nearly two times more likely to terminate therapy.“

Since untreated sleep apnoea increases the risk of other chronic diseases such as hypertension, morbid obesity, type 2 diabetes and stroke, these findings underline the importance of regularly monitoring patients to support adherence to treatment.

It has also been shown that switching treatment from continuous PAP to adaptive servo-ventilation therapy can significantly improve adherence, as those with treatment-emergent CSA who switched to ASV used their therapy longer and had significantly fewer apnoeas during sleep.

Dr Carlos Nunez, ResMed's chief medical officer, said the findings "underscore the importance of keeping patients on therapy through regular monitoring, and rethinking the conventional wisdom on therapeutic options based on each patient's disease severity".

With over 20 years of experience within the medical devices market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current medical device roles we have available, you can search for the latest job roles, register your details, or contact the team today.

See all the latest jobs in Medical Devices
Return to news